Citius Pharmaceuticals, Inc. (CTXR)

Citius Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	26.52	41.75	70.11	13.92	7.95
Cash & Cash Equivalents	26.52	41.75	70.11	13.92	7.95
Cash Growth	-36.48%	-40.45%	403.79%	75.03%	-13.45%
Other Current Assets	7.85	2.81	2.7	0.07	-0.01
Total Current Assets	34.37	44.56	72.81	13.98	7.94
Property, Plant & Equipment	0.46	0.65	0.83	0.99	0
Goodwill and Intangibles	9.35	9.35	9.35	9.35	9.35
Other Long-Term Assets	59.44	59.44	59.44	19.46	19.46
Total Long-Term Assets	69.24	69.44	69.61	29.79	28.8
Total Assets	103.61	114	142.43	43.77	36.75
Accounts Payable	2.93	1.17	1.28	1.86	2.71
Current Debt	0.22	0.2	0.18	0.33	0.17
Other Current Liabilities	2.63	3.17	2.53	1.91	1.72
Total Current Liabilities	5.78	4.53	3.98	4.1	4.61
Long-Term Debt	0.26	0.48	0.68	1.02	0
Other Long-Term Liabilities	6.14	5.56	4.99	4.99	4.99
Total Long-Term Liabilities	6.4	6.04	5.66	6.01	4.99
Total Liabilities	12.18	10.57	9.65	10.1	9.59
Total Debt	0.48	0.68	0.86	1.35	0.17
Debt Growth	-29.04%	-20.72%	-36.73%	681.65%	-
Retained Earnings	-162.23	-129.69	-96.05	-70.59	-53.05
Shareholders' Equity	90.83	102.83	132.18	33.67	27.15
Net Cash / Debt	26.04	41.07	69.26	12.56	7.78
Net Cash / Debt Growth	-36.60%	-40.70%	451.19%	61.54%	-13.71%
Net Cash Per Share	0.17	0.28	0.64	0.32	0.39
Working Capital	28.59	40.03	68.83	9.88	3.33
Book Value Per Share	0.60	0.70	1.22	0.86	1.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).